Health & Biotech
Health & Biotech
ASX Health Stocks: Healius tracks guidance, wants to focus on pathology and imaging
Health & Biotech
Nutritional Growth Solutions to unlock US market for toddler formula amid infant formula crisis
Health & Biotech
Wellnex raises $6.2 million to fast-track entry into OTC medicinal cannabis market
Health & Biotech
CardieX gets hearts racing as MST Access reaffirms value at 5x current share price
Health & Biotech
ASX Health Stocks: Alterity is set to launch Phase 2 clinical trial on Multiple System Atrophy
Health & Biotech
EZZ taps into strong consumer demand for ethically, locally made personal care products
Health & Biotech
Here’s how Immutep and other immunotherapy biotechs have changed cancer treatment
Health & Biotech
ASX Health Stocks: Mesoblast’s Q3 revenues, Osprey restructures business to reduce debt
Health & Biotech
Medlab wants to get right up COVID’s nose, as nasal vaccine program gathers steam
Health & Biotech
Significant milestone in Dimerix’s Phase 3 trial on kidney disease, with first patient recruited
Health & Biotech
ASX Health Stocks: Anteris implants its novel aortic valve DurAVR into 8 more patients
Health & Biotech
ASX Health Stocks: Invion demonstrates efficacy, Biotron gets feedback from the FDA
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.